11
Participants
Start Date
April 30, 2011
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
5-Azacitidine
"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
Roswell Park Cancer Institute, Buffalo
University of Utah, Salt Lake City
Oregon Health and Science University, Portland
Collaborators (1)
Celgene
INDUSTRY
University of Utah
OTHER